Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin and melijent in chronic kidney failure patients
IRCT20230607058409N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Shahid Beheshti University of Medical Sciences. Started Jun 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20230607058409N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230607058409N1.